Antibody to hepatitis C virus increases with time on hemodialysis.
Antibody to hepatitis C virus increases with time on hemodialysis.
复制标题
丙型肝炎病毒抗体随着血液透析时间的延长而增加。
作者：
Hardy Nm;S. Sandroni;S. Danielson;Wilson Wj
我们研究了慢性血液透析是否与接触丙型肝炎病毒的风险增加有关。利用第一代酶联免疫吸附试验(C-100 EL ISA，新泽西州Raritan，Ortho诊断系统)和CHIBA丙型肝炎病毒第二代检测(RIBA，CHIBA，Emeryville，CA和Ortho诊断系统，新泽西州Raritan)，在87名血液透析患者中有31人(36%)发现了丙型肝炎病毒抗体。血液透析<2年的患者抗体发生率为15%(n=46)，而透析大于或等于2年的患者抗体发生率为59%(n=41)。我们无法证明丙型肝炎病毒抗体阳性与输血史之间的相关性。总体发病率高于之前报道的美国血液透析患者的发病率。在透析超过或等于2年的患者中发现了非常高的发病率，这表明血液透析单元中的因素可能有助于病毒的传播。
We studied whether chronic hemodialysis is associated with an increased risk of exposure to hepatitis C virus. Utilizing a first generation Elisa assay (C-100 Elisa, Ortho Diagnostic Systems, Raritan, NJ) and the Chiron RIBA HCV second generation assay (RIBA, Chiron, Emeryville, CA and Ortho Diagnostic Systems, Raritan, NJ), antibody to HCV was found in 31 of 87 hemodialysis patients (36%). Patients on hemodialysis less than 2 years had an antibody incidence of 15% (n = 46), as contrasted with a 59% incidence for patients on dialysis greater than or equal to 2 years (n = 41). We were unable to demonstrate a correlation of HCV-antibody positivity with history of blood transfusion. The overall incidence is higher than previously reported for hemodialysis patients in the United States. The very high incidence found in patients on dialysis greater than or equal to 2 years suggests that factors in the hemodialysis unit might contribute to the spread of virus.